Presentation is loading. Please wait.

Presentation is loading. Please wait.

Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer  Mohammad Chakra, MD, Jean Louis Pujol,

Published byKudret Kubat Modified over 5 years ago

Similar presentations

Presentation on theme: "Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer  Mohammad Chakra, MD, Jean Louis Pujol,"— Presentation transcript:

1 Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer  Mohammad Chakra, MD, Jean Louis Pujol, MD, PhD, Pierre-Jean Lamy, MD, Marie Cecile Bozonnat, BSc, Xavier Quantin, MD, PhD, William Jacot, MD, PhD, Jean-Pierre Daurès, MD, PhD  Journal of Thoracic Oncology  Volume 3, Issue 10, Pages (October 2008) DOI: /JTO.0b013e e Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Receiver operating characteristic constructed using the sensitivity–specificity relationship circulating vascular endothelial growth factor (VEGF) serum to discriminate non-small cell lung cancer (NSCLC) patients and patients with a nonmalignant pulmonary disease. AUC, area under the curve; SE, standard error. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e e) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Circulating vascular endothelial growth factor (VEGF) serum distribution according to Mountain stage grouping in non-small cell lung cancer (6th edition of the staging system). Horizontal bar, median value; columns, interquartile range; vertical bar, 95% confidence interval. Kruskal–Wallis test: 11.2; p = 0.01. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e e) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Circulating vascular endothelial growth factor (VEGF) serum distribution according to the nodal status in non-small cell lung cancer. Horizontal bar, median value; columns, interquartile range; vertical bar, 95% confidence interval. Kruskal–Wallis test: 11.1; p = 0.01. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e e) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Circulating vascular endothelial growth factor (VEGF) serum distribution according to performance status in non-small cell lung cancer. Horizontal bar, median value; columns, interquartile range; vertical bar, 95% confidence interval. Kruskal–Wallis test: 26.6; p < Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e e) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 Probability of survival of non-small cell lung cancer patients with normal and elevated pretreatment circulating vascular endothelial growth factor (VEGF) serum level; Kaplan–Meier curves were constructed taking into account the whole population survival. Dotted line, circulating VEGF serum >600 pg/mL; dark line, circulating VEGF serum ≤600 pg/mL. Median survival in months [95% CI]: 6.4 [ ] and 10.6 [ ], respectively, log-rank: p = Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e e) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer  Mohammad Chakra, MD, Jean Louis Pujol,"

Similar presentations

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma  Yingjie.

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma  Yingjie.
Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.

Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Zachary S. Morris, MD, PhD, Donald M. Cannon, MD, Brett A

Zachary S. Morris, MD, PhD, Donald M. Cannon, MD, Brett A
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.

Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer? 

Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer? 
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.
The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.
The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,
Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,
Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis  Ping Zhan, MD,

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis  Ping Zhan, MD,
Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib  Sai-Hong Ignatius Ou, MD, PhD,

Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib  Sai-Hong Ignatius Ou, MD, PhD,
Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 

Similar presentations

Ads by Google